🇺🇸 FDA
Pipeline program

177Lu-DOTA-TLX591

177Lu-TLX591-001

Phase 1 mab completed

Quick answer

177Lu-DOTA-TLX591 for Metastatic Prostate Cancer is a Phase 1 program (mab) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Telix Pharmaceuticals Ltd
Indication
Metastatic Prostate Cancer
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials